CHRO Chromocell Therapeutics Corporation

USD 1.62 0.02 1.25
Icon

Chromocell Therapeutics Corporation (CHRO) Stock Analysis and Price Targets

| Other | NYE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.62

+0.02 (+1.25)%

N/A

5.22K

N/A

N/A

Icon

CHRO

Chromocell Therapeutics Corporation (USD)
| NYE
USD 1.62
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

N/A

N/A

USD 1.62

Chromocell Therapeutics Corporation (CHRO) Stock Forecast

N/A

Based on the Chromocell Therapeutics Corporation stock forecast from 0 analysts, the average analyst target price for Chromocell Therapeutics Corporation is not available over the next 12 months. Chromocell Therapeutics Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Chromocell Therapeutics Corporation is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Chromocell Therapeutics Corporation’s stock price was USD 1.62. Chromocell Therapeutics Corporation’s stock price has changed by +15.71% over the past week, -38.17% over the past month and 0% over the last year.

No recent analyst target price found for Chromocell Therapeutics Corporation
No recent average analyst rating found for Chromocell Therapeutics Corporation

Company Overview Chromocell Therapeutics Corporation

N/A

N/A

N/A

N/A

USD

USA

Adjusted Closing Price for Chromocell Therapeutics Corporation (CHRO)

Loading...

Unadjusted Closing Price for Chromocell Therapeutics Corporation (CHRO)

Loading...

Share Trading Volume for Chromocell Therapeutics Corporation Shares

Loading...

Compare Performance of Chromocell Therapeutics Corporation Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CHRO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Chromocell Therapeutics Corporation (Sector: Other )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PRH
Prudential Financial Inc. 5.95.. +0.15 (+0.60%) USD10.68B 1.40 N/A

ETFs Containing CHRO

Symbol Name CHRO's Weight Expense Ratio Price(Change) Market Cap
SXIPEX:SW
iShares STOXX Europe 600 .. 11.01 % 0.00 % +0.25 (+0.68%) USD0.09B

Frequently Asked Questions About Chromocell Therapeutics Corporation (CHRO) Stock

Stock Target Advisor's fundamental analysis for Chromocell Therapeutics Corporation's stock is Neutral.

Unfortunately we do not have enough data on CHRO's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CHRO's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on CHRO's stock to indicate if its overvalued.

The last closing price of CHRO's stock was USD 1.62.

Unfortunately we do not currently have any market capitalization data for CHRO's stock.

Unfortunately we do not have enough analyst data on CHRO's stock to indicate whether its price will go up or not.

Following are ETFs with the highest allocation to Chromocell Therapeutics Corporation's stock :

SXIPEX:SW

Sorry, we do not have any data on the number of employees for Chromocell Therapeutics Corporation.

Sorry we do not have any infomation available on Chromocell Therapeutics Corporation's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...